Schlintl, V., Huemer, F., Greil, R., & Weiss, L. (2021). Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. J Gastrointest Oncol.
Stile di citazione ChicagoSchlintl, Verena, Florian Huemer, Richard Greil, e Lukas Weiss. "Ramucirumab Plus FOLFIRI or Irinotecan As Second-line Therapy in Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma." J Gastrointest Oncol 2021.
Citazione MLASchlintl, Verena, Florian Huemer, Richard Greil, e Lukas Weiss. "Ramucirumab Plus FOLFIRI or Irinotecan As Second-line Therapy in Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma." J Gastrointest Oncol 2021.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.